Bayberry Allergy Shots: Coastal Southeast SCIT Guide (Myricaceae)
Bayberry (Morella cerifera, family Myricaceae — not Myrtaceae) is the underdocumented major aeroallergen of the coastal Southeast, with the Jacinto 1992 JACI provocation study showing 15% SPT positivity, 92% positive nasal challenges, and 57% positive bronchial challenges in sensitized subjects. Despite having no IUIS-named allergen and no SCIT RCT, bayberry has more clinical provocation evidence than many formally characterized tree species.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Bayberry (Southern Wax Myrtle)is covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Bayberry (Southern Wax Myrtle) Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to bayberry (southern wax myrtle) — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of bayberry (southern wax myrtle) allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of bayberry (southern wax myrtle) immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of bayberry (southern wax myrtle) extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for bayberry (southern wax myrtle) allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing bayberry (southern wax myrtle) extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription bayberry (southern wax myrtle) immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat bayberry (southern wax myrtle) allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Bayberry (Southern Wax Myrtle)?
The biology, taxonomy, and clinical fingerprint of Bayberry (Southern Wax Myrtle) — the foundation of how SCIT targets it.
Bayberry / southern wax myrtle (Morella cerifera, family Myricaceae) releasing wind-borne pollen from catkins in the coastal Southeast, February–April. The aromatic waxy berries are post-pollination structures and do not drive IgE allergy.
- Scientific name
- Morella cerifera (syn. Myrica cerifera)
- Family
- MyricaceaeBayberry family — NOT Myrtaceae (a common botanical error in older sources)
- Type
- Evergreen shrub/small tree pollen (wind-pollinated)
- Native to
- Atlantic and Gulf coastal plain, from New Jersey south to Florida and west to Texas
- Allergen proteins
- No IUIS-named Morella or Myrica allergen as of May 2026 — molecular allergen catalogue is empty
- Particle size
- N/A — pollen size not formally characterized in IgE literature
- Avoidance difficulty
- Very difficult
How Bayberry (Southern Wax Myrtle) Allergy Presents
Symptoms by body system — useful for distinguishing Bayberry (Southern Wax Myrtle) sensitivity from overlapping allergies and infections.
Respiratory
- Sneezing and nasal congestion during February–April pollen release in the coastal SE
- Clear rhinorrhea confirmed as allergen-specific in 92% of nasal challenges per Jacinto 1992
- Asthma exacerbation — 57% of sensitized asthmatics showed positive bronchial challenges in Jacinto 1992
- Symptoms overlap with co-occurring live oak, pecan, and bayberry season making differential diagnosis important
- Earlier season onset than most spring tree pollens — February in Florida and coastal Georgia
Ocular
- Itchy, watery eyes during the February–April coastal pollen season
- Allergic conjunctivitis concurrent with nasal symptoms in sensitized individuals
- Periorbital swelling in patients with high IgE burden to bayberry
Dermal
- No documented OAS food cross-reactivity for Morella cerifera pollen allergens
- Contact dermatitis from bayberry wax or leaf preparations is rarely reported
- The aromatic berries used in candles are post-pollination structures and do not drive pollen IgE allergy
Systemic
- Fatigue from chronic allergic rhinitis during the extended coastal SE spring season
- Sleep disruption from nasal congestion in residents of coastal Georgia, Carolinas, and Florida
- Asthma exacerbations — the 57% positive bronchial challenge rate (Jacinto 1992) supports systemic impact in asthmatics
- Headache from chronic sinus inflammation during February–April
Southern bayberry deserves more clinical attention than it gets — Jacinto's 1992 bronchial challenge data show 57% asthma provocation positivity in sensitized patients, comparable to many IUIS-characterized species, yet the IUIS allergen catalogue still lists nothing for Morella cerifera. That is an evidence gap, not a reason to dismiss the allergen.
When & Where Bayberry (Southern Wax Myrtle) Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: March across the coastal Southeast; February in Florida and coastal Georgia· ~6–8 weeks from February through April along the Atlantic and Gulf coastal plain
US Exposure Map
8 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Low
- MT:
- Low
- ND:
- Low
- MN:
- Low
- WI:
- Low
- MI:
- Low
- NY:
- Low
- MA:
- Low
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Low
- IL:
- Low
- IN:
- Low
- OH:
- Low
- PA:
- Low
- NJ:
- Moderate
- CT:
- Low
- RI:
- Low
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- Low
- MO:
- Low
- KY:
- Low
- WV:
- Low
- VA:
- Moderate
- MD:
- Moderate
- DE:
- Moderate
- AZ:
- Low
- NM:
- Low
- KS:
- Low
- AR:
- Moderate
- TN:
- Moderate
- NC:
- High
- SC:
- High
- OK:
- Low
- LA:
- High
- MS:
- High
- AL:
- High
- GA:
- High
- TX:
- High
- FL:
- High
- AK:
- Low
- HI:
- Low
What Bayberry (Southern Wax Myrtle) Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Bayberry cross-reactivity is incompletely characterized — possible Betulaceae (Fagales) cross-reactivity has been suggested but not formally quantified; no OAS food list exists for Morella cerifera sensitization.
Possible Betulaceae cross-reactivity suggested but not formally quantified; shared Myricales-Fagales evolutionary proximity
Is SCIT Right for Your Bayberry (Southern Wax Myrtle) Allergy?
Answer five questions to assess whether bayberry allergy shots may be appropriate for your coastal Southeast spring allergy profile.
How severe are your February–April coastal SE allergy symptoms?
The Bayberry (Southern Wax Myrtle) SCIT Protocol
Bayberry SCIT uses non-standardized aqueous Morella cerifera extract, typically included in a southeastern X-tree prescription mix alongside live oak, pecan, and other regionally confirmed aeroallergens. Curex IgE testing differentiates bayberry sensitization from co-occurring SE aeroallergens like live oak, bald cypress, and bahiagrass that share the February–April symptom window — a critical step before designing a regional SCIT mix.
Starting from a highly dilute concentration (Curex begins at 1:100,000 w/v — more conservative than the textbook 1:10,000), the bayberry extract concentration is incrementally increased at each step. With Curex, the prescribing physician supervises the first injection from each new vial or concentration live in the Virtual Shot Room and confirms a prescribed epinephrine auto-injector on hand. Initiating build-up in fall allows reaching maintenance before the February–April coastal SE pollen season.
Ongoing maintenance injections sustain the immunologic tolerance developed during the build-up phase. The Jacinto 1992 provocation data provide the clinical justification for bayberry inclusion, though no maintenance-efficacy RCT exists specifically for this species.
After a complete SCIT course, lasting benefit extending 7–12 additional years is expected based on the broader tree-pollen SCIT literature. The decision to discontinue is individualized, particularly for patients with comorbid asthma where the 57% positive bronchial challenge rate (Jacinto 1992) indicates high respiratory risk from untreated sensitization.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Bayberry (Southern Wax Myrtle) SCIT
Bayberry has no species-specific SCIT RCT, but Jacinto et al. (JACI 1992) provides the strongest provocation evidence of any non-IUIS-characterized tree allergen in the southeastern US — 92% positive nasal challenges and 57% positive bronchial challenges in sensitized subjects.
- Positive nasal challenge in sensitized SE rhinitis subjects92%Jacinto CM, Nelson RP Jr, Bucholtz GA et al. JACI 1992;90:312 — N=13 sensitized rhinitis subjects
- Positive bronchial challenge in sensitized SE asthmatic subjects57%Jacinto CM, Nelson RP Jr, Bucholtz GA et al. JACI 1992;90:312 — sensitized asthmatic subjects
- SPT positivity to bayberry in a 400-patient SE allergic cohort15%Jacinto CM, Nelson RP Jr, Bucholtz GA et al. JACI 1992;90:312 — 60/400 patients
Bayberry has the strongest provocation evidence of any non-IUIS-characterized tree allergen in the southeastern US — the Jacinto 1992 nasal and bronchial challenge data are the gold standard of clinical evidence short of an RCT. No species-specific SCIT efficacy trial exists, so clinical practice extrapolates from the AAAAI Practice Parameter framework (Cox et al., JACI 2011) and regional empirical data. Patients should understand that bayberry SCIT response is likely but not RCT-proven.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Bayberry (Southern Wax Myrtle) SCIT Side Effects
Bayberry SCIT follows the standard inhalant immunotherapy safety profile; no bayberry-specific adverse reaction signal has been reported beyond the class-level SCIT literature.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling and redness Expected; resolves within 1–2 hours; ice application reduces discomfort | Rate 30–50% | Mild |
Injection-site pruritus Normal histamine response at the injection site during dose escalation | Rate 25–40% | Mild |
Large local reaction (>5 cm) Triggers dose adjustment; does not predict systemic risk | Rate 5–10% | Moderate |
Persistent induration at injection site Resolves within 24–48 hours; site rotation reduces frequency | Rate 2–5% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Generalized urticaria or pruritus Requires immediate antihistamine administration and dose review | Rate 0.1–0.5% per injection | Moderate |
Rhinitis or conjunctivitis flare Manageable with standard antiallergic medications | Rate 0.1–0.3% per injection | Mild |
Bronchospasm Higher vigilance warranted given 57% positive bronchial challenge rate in sensitized asthmatics | Rate 0.05–0.1% per injection | Moderate |
Anaphylaxis Curex supervises the first injection from each new vial or concentration live in the Virtual Shot Room with a prescribed epinephrine auto-injector confirmed on hand | Rate <0.01% per injection | Severe |
Bayberry-sensitized asthmatics warrant extra vigilance given the documented 57% bronchial challenge positivity rate in this population (Jacinto 1992). With Curex at-home SCIT, the prescribing physician supervises the first injection from each new vial or concentration live in the Virtual Shot Room, confirms a prescribed epinephrine auto-injector on hand before the first injection, and checks asthma control (spirometry) before each dose.
SCIT vs Alternatives for Bayberry (Southern Wax Myrtle)
For bayberry-allergic patients in the coastal Southeast, SCIT is the only disease-modifying option; pharmacotherapy provides symptom relief but no lasting benefit after stopping treatment.
| Criterion | At-Home SCIT (Curex)Best | SLIT Drops | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | Moderate (provocation-validated) | Limited (extrapolated) | Minimal (ubiquitous coastal shrub) | Good symptom control |
| 5-yr cost | $3,500–$15,000 | $1,500–$4,000 | $0–$300/yr | $200–$1,200/yr |
| Duration | 3–5 years | 3–5 years | Indefinite | Indefinite |
| Convenience | At-home weekly self-injection; maintenance on a schedule individualized by your allergist | Daily at home | Lifestyle adjustments | Daily pills/sprays |
| Safety | Virtual Shot Room–supervised dosing + prescribed epi confirmed on hand | Self-administered | No medical risk | Generally safe |
| Lasting effect | 7–12 yrs post-course | Ongoing use needed | No lasting change | No lasting change |
At-Home SCIT (Curex)Best
SLIT Drops
Avoidance
Medications
For coastal SE patients with confirmed bayberry sensitization and inadequate pharmacotherapy response, SCIT incorporating bayberry alongside regional co-allergens is the evidence-based next step. Curex IgE testing distinguishes bayberry from the co-occurring aeroallergens, and Curex now delivers that SCIT as an at-home allergy shot with pricing confirmed in a current program quote: a bayberry-inclusive serum compounded under USP <797>, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room, a prescribed epinephrine auto-injector confirmed on hand, and allergist-overseen escalation — for patients who prefer at-home therapy.
What Bayberry (Southern Wax Myrtle) SCIT Actually Costs
Bayberry SCIT is billed under standard immunotherapy CPT codes (95115, 95117, 95165) as part of a southeastern X-tree mix. Most major insurers cover it when prescribed by a board-certified allergist with documented sensitization. Prior authorization requirements vary; some payers require documented pharmacotherapy failure before approving immunotherapy for non-standardized tree extracts.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your bayberry (southern wax myrtle) allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Bayberry (Southern Wax Myrtle) SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Bayberry (Morella cerifera, also called southern wax myrtle) is an evergreen shrub or small tree native to the Atlantic and Gulf coastal plain from New Jersey to Florida and west to Texas. Unlike most ornamental plants, bayberry is wind-pollinated — its pollen is released from catkins and carried through the air, allowing it to reach nasal passages and trigger IgE-mediated allergic rhinitis and asthma in sensitized individuals. The Jacinto et al. (JACI 1992) study confirmed this mechanism directly: 15% of 400 southeastern allergic patients tested positive on skin prick test, and 92% of sensitized rhinitis subjects produced positive nasal challenge responses when exposed to the extract. Bayberry is also widely planted as a residential landscape shrub in coastal communities, extending exposure beyond wildland settings.
No — this is a common botanical error. Bayberry (Morella cerifera) belongs to family Myricaceae, while eucalyptus (Eucalyptus globulus) and melaleuca (Melaleuca quinquenervia) belong to family Myrtaceae. Despite the similar-sounding names, Myricaceae and Myrtaceae are completely unrelated plant families with different allergen profiles and different clinical significance. This distinction matters for allergy testing: a positive bayberry result does not imply cross-reactivity with eucalyptus or melaleuca, and the families should not be substituted for each other in SCIT extract preparation. Some older commercial allergen panel labels incorrectly list bayberry under Myrtaceae — verify the correct family with your allergist.
The southeastern US spring season (February–April) features multiple overlapping aeroallergens — live oak, pecan, bayberry, sweet gum, and sycamore all shed pollen in this window. Bayberry's distinguishing features are its provocation evidence (Jacinto 1992 showing 57% positive bronchial challenges in asthmatics), its coastal distribution (concentrated in the Atlantic and Gulf coastal plain rather than inland), and its Myricaceae family membership, which may reflect a different molecular sensitization pattern from the oak-pecan Fagales cluster. Differential testing — including skin tests to multiple spring tree species — is necessary to identify which allergen is the primary driver of your symptoms before designing an immunotherapy mix.
There is one foundational provocation study for bayberry — Jacinto CM, Nelson RP Jr, Bucholtz GA, et al. (JACI 1992;90:312), which demonstrated 15% SPT positivity in 400 southeastern allergic patients, 92% positive nasal challenges in sensitized rhinitis subjects, and 57% positive bronchial challenges in sensitized asthmatic subjects. This is provocation evidence, not a SCIT efficacy trial. No randomized controlled trial evaluating bayberry-specific immunotherapy has been published as of May 2026, and bayberry has no formally named IUIS molecular allergen. Clinical inclusion in southeastern SCIT mixes is based on the Jacinto 1992 evidence and regional empirical practice aligned with the AAAAI Practice Parameter framework.
Bayberry (Morella cerifera) peaks in March across most of the coastal Southeast, with pollen release beginning as early as February in Florida and coastal Georgia and extending through April in the mid-Atlantic coastal plain. The season typically lasts 6–8 weeks. Because bayberry overlaps significantly with live oak (March–April), pecan (April), and sweet gum (March–April) in the same geographic region, the combined spring tree-pollen burden in coastal southeastern states can be prolonged and severe. Per Anderegg et al. (PNAS 2021), North American tree-pollen seasons have shifted approximately 20 days earlier since 1990, so February symptoms in coastal Florida are becoming more common.
Yes — the Jacinto 1992 JACI data directly demonstrated 57% positive bronchial challenge responses in bayberry-sensitized asthmatic subjects. This means that for coastal southeastern asthmatic patients with bayberry sensitization, bayberry pollen exposure may trigger or worsen bronchospasm during the February–April season. Asthmatic patients being evaluated for bayberry SCIT should have their asthma well-controlled (FEV1 >70% predicted) at the time of each injection. A board-certified allergist will coordinate asthma management with SCIT dose escalation. Spirometry control is required before each SCIT visit in asthmatic patients.
Bayberry SCIT is billed as part of a southeastern X-tree prescription mix under standard immunotherapy CPT codes (95115 single injection, 95117 multiple injections, 95165 extract preparation). Most major US health insurers cover regionally appropriate tree-pollen SCIT when prescribed by a board-certified allergist with documented IgE-mediated sensitization confirmed by skin test or specific IgE. Prior authorization is typically required, and some plans require documented failure of pharmacotherapy (antihistamines plus intranasal corticosteroids for 6–12 months) before approving immunotherapy. Contact your insurer before initiating treatment to confirm coverage terms and any applicable prior authorization requirements.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.